.
.

That question has bedeviled the field of T-cell immunotherapy, even as it has raced into the clinic. Novartis’ Kymriah, approved last year to treat a form of pediatric leukemia, is expected to receive additional federal approval this week to treat an aggressive type of adult lymphoma. Another T-cell therapy, Gilead’s Yescarta, also treats lymphoma.

Now, University of Pennsylvania researchers, who developed Kymriah with drugmaker Novartis, believe they’ve found an explanation for treatment failures — and it shows the still-mysterious variety and interaction of T cells, the soldier blood cells that fight infection and cancer.

. .
An orange tree that is infected with huanglongbing. Leaf symptoms begin on one or a few branches and slowly spread to the rest of the tree. Credit: Georgios Vidalakis, UC Riverside

Researchers at the University of California, Riverside have made an important step in understanding the molecular mechanism of huanglongbing (HLB), a destructive disease that is a serious threat to the citrus industry worldwide.

http://cial20mg.life/Hirtz-brother-of-Prante-from-Mupayepaye?Narkiermo=278
View .

Covered services

Doctor with female patient

(Getty Images)

. .
. .
Internet
.
Audio
  • Meetings